Literature DB >> 10499365

Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman.

G Lallement1, D Baubichon, D Clarençon, M Galonnier, M Peoc'h, P Carpentier.   

Abstract

Today, organophosphorus nerve agents are still considered as potential threats in both military or terrorism situations. These agents act as potent irreversible inhibitors of acetylcholinesterase in both central and peripheral nervous systems. Conventional treatment of organophosphate poisoning includes the combined administration of a cholinesterase reactivator (an oxime), a muscarinic cholinergic receptor antagonist (atropine) and a benzodiazepine anticonvulsant (diazepam). However, numerous studies have demonstrated that the excitatory amino acid glutamate also plays a prominent role in the maintenance of organophosphate-induced seizures and in the subsequent neuropathology especially through an overactivation of the N-methyl-D-aspartate (NMDA) receptor subtype. Contrary to other non-competitive NMDA antagonists successfully tested in rodents exposed to organophosphate, gacyclidine is a novel antiNMDA compound which is in the process of approval for human use in France for neurotraumatology. This review summarizes the therapeutic value of gacyclidine as a complement to the available emergency treatment against severe organophosphate poisoning. Previous data obtained from experiments on primates in several scenarios mimicking military or terrorist attacks, using soman as the nerve agent, were used. Primates pretreated with pyridostigmine and receiving conventional emergency therapy at the first signs of poisoning survive. However, only gacyclidine is able to ensure complete management of nerve agent poisoning for rapid normalization of EEG activity, clinical recovery and neuroprotection. Gacyclidine also ensures optimal management of severe nerve agent poisoning in animals neither pretreated nor receiving emergency therapy likewise during an unexpected exposure. However, this beneficial effect is obtained provided that medical intervention is conducted rapidly after intoxication. Globally, the current lack of any other NMDA receptor antagonist suitable for human use reinforces the therapeutic value of gacyclidine as a central nervous system protective agent for the treatment of OP poisoning.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499365

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  7 in total

Review 1.  Organophosphorus poisoning (acute).

Authors:  Peter G Blain
Journal:  BMJ Clin Evid       Date:  2011-05-17

2.  Organophosphorous Poisoning : an Evidence Based Approach.

Authors:  Surjit Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Animal models that best reproduce the clinical manifestations of human intoxication with organophosphorus compounds.

Authors:  Edna F R Pereira; Yasco Aracava; Louis J DeTolla; E Jeffrey Beecham; G William Basinger; Edgar J Wakayama; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2014-06-06       Impact factor: 4.030

4.  The need for translational research on antidotes for pesticide poisoning.

Authors:  Nick A Buckley; Michael Eddleston; Andrew H Dawson
Journal:  Clin Exp Pharmacol Physiol       Date:  2005-11       Impact factor: 2.557

Review 5.  Organophosphorus poisoning (acute).

Authors: 
Journal:  BMJ Clin Evid       Date:  2007-03-01

6.  MRS of brain metabolite levels demonstrates the ability of scavenging of excess brain glutamate to protect against nerve agent induced seizures.

Authors:  Angela Ruban; Inbal E Biton; Arik Markovich; David Mirelman
Journal:  Int J Mol Sci       Date:  2015-02-02       Impact factor: 5.923

7.  Advances in toxicology and medical treatment of chemical warfare nerve agents.

Authors:  Mohammd Moshiri; Emadodin Darchini-Maragheh; Mahdi Balali-Mood
Journal:  Daru       Date:  2012-11-28       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.